TCF Stock Overview
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Theracryf Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0075 |
| 52 Week High | UK£0.041 |
| 52 Week Low | UK£0.007 |
| Beta | 1.44 |
| 1 Month Change | -6.25% |
| 3 Month Change | -51.61% |
| 1 Year Change | -79.45% |
| 3 Year Change | -90.45% |
| 5 Year Change | -96.10% |
| Change since IPO | -97.86% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Oct 11
We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely
Nov 24Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Aug 06Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?
Apr 09We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate
Dec 25Shareholder Returns
| TCF | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.3% | 5.9% | 1.0% |
| 1Y | -79.5% | -26.7% | 3.0% |
Return vs Industry: TCF underperformed the UK Biotechs industry which returned -26.8% over the past year.
Return vs Market: TCF underperformed the UK Market which returned 3% over the past year.
Price Volatility
| TCF volatility | |
|---|---|
| TCF Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: TCF's share price has been volatile over the past 3 months.
Volatility Over Time: TCF's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Huw Jones | theracryf.com |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy.
Theracryf Plc Fundamentals Summary
| TCF fundamental statistics | |
|---|---|
| Market cap | UK£3.21m |
| Earnings (TTM) | -UK£3.35m |
| Revenue (TTM) | UK£838.00k |
3.8x
P/S Ratio-1.0x
P/E RatioIs TCF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCF income statement (TTM) | |
|---|---|
| Revenue | UK£838.00k |
| Cost of Revenue | UK£5.17m |
| Gross Profit | -UK£4.33m |
| Other Expenses | -UK£974.00k |
| Earnings | -UK£3.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0078 |
| Gross Margin | -516.35% |
| Net Profit Margin | -400.12% |
| Debt/Equity Ratio | 0% |
How did TCF perform over the long term?
See historical performance and comparison